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Aims: To assess the diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for
undiagnosed T2DM and to compare its performance with the Latin-American FINDRISC
(LA-FINDRISC) and the Peruvian Risk Score.
Materials and methods: A population-based study was conducted. T2DM and undiagnosed
T2DM were defined using oral glucose tolerance test (OGTT). Risk scores assessed were
FINDRISC, LA-FINDRISC and Peruvian Risk Score. Diagnostic accuracy of risk scores was
estimated using the c-statistic and the area under the ROC curve (aROC). A simplified version
of  FINDRISC was also derived.
Results: Data from 1609 individuals, mean age 48.2 (SD: 10.6), 810 (50.3%) women, were col-
lected. A total of 176 (11.0%; 95%CI: 9.4%–12.5%) were classified as having T2DM, and 71 (4.7%;
95%CI: 3.7%–5.8%) were classified as having undiagnosed T2DM. Diagnostic accuracy of the
FINDRISC (aROC = 0.69), LA-FINDRISC (aROC = 0.68), and Peruvian Risk Score (aROC = 0.64)
was  similar (p = 0.15). The simplified FINDRISC, with 4 variables, had a slightly better perfor-
mance (aROC = 0.71) than the other scores.
Conclusion: The performance of FINDRISC, LA-FINDRISC and Peruvian Risk Score for undi-
agnosed T2DM was similar. A simplified FINDRISC can perform as well or better for
undiagnosed T2DM. The FINDRISC may be useful to detect cases of undiagnosed T2DM
in  resource-constrained settings.
©  2018 The Author(s). Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.
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1.  Introduction
Globally, there is an increase in the burden of type 2
diabetes mellitus (T2DM): the age-standardized prevalence
of T2DM has increased from 4.3% to 9.0% among men
and from 5.0% to 7.9% among women in the last four
decades [1]. T2DM is also responsible for about 2 mil-
lion deaths every year worldwide [2,3] and USD 825 billion
are estimated to be spent in T2DM-related healthcare
[1,4].
Identifying individuals with undiagnosed T2DM can be
an important approach to prevent or delay T2DM compli-
cations [5], though, universal screening for T2DM at the
population level is still controversial [6]. Thus, although, the
American Diabetes Association recommends T2DM testing
for all adults starting at age 45 years regardless of weight, or
those who  are overweight or obese and have one or more
additional risk factor for T2DM [7]; the Disease Control Pri-
orities group recommends testing individuals at high-risk of
T2DM (i.e. those aged ≥40 years, individuals with family his-
tory of T2DM, obesity, physical inactivity, or dyslipidemia)
[6].
The identification of T2DM cases can be better addressed
using a two-step approach. Thus, in the first step, a risk score
– defined as “an objective assessment of the probability of the
presence or future development of an adverse health condi-
tion” [8] – can be applied to identify subjects at high risk of
having or developing T2DM, and, in the second step, a confir-
matory test (fasting glucose, oral glucose tolerance test [OGTT]
or glycated hemoglobin [HbA1c]) can be performed, but only
among those categorized as high risk in the previous step
[9].
Different risk models, also known as risk scores, have been
developed to detect T2DM cases. Some of them are useful to
detect undiagnosed (prevalent) T2DM cases, whereas other
ones predict the development of new (incident) T2DM cases
[10]. The Finnish Diabetes Risk Score (FINDRISC) is a ques-
tionnaire to identify individuals at high risk of developing
T2DM, and was created using a prospective cohort of indi-
viduals aged between 35 and 64 years [11]. Original questions
included age, body mass index, waist circumference, physi-
cal activity, daily consumption of fruits, berries or vegetables,
history of anti-hypertensive drug treatment, and history of
high blood glucose [12]. However, later studies added fam-
ily history of T2DM to the model and modified diet patterns
and physical activity questions. Despite being widely used
for estimating the risk of developing T2DM within the fol-
lowing ten years, the FINDRISC has been also evaluated as a
tool to identify undiagnosed T2DM, abnormal glucose toler-
ance and metabolic syndrome [13–15]. Although this score is
widely used in many  Latin America settings [16,17] and even
a Latin America FINDRISC (LA-FINDRISC) has been described
[18], its diagnostic accuracy needs to be assessed in other
resource-constrained settings. Therefore, this study aimed
to assess the diagnostic accuracy of the FINDRISC for undi-
agnosed T2DM. In addition, we  compared the performance
of the FINDRISC, the LA-FINDRISC and the Peruvian Risk
Score.
2.  Materials  and  methods
2.1.  Source  of  data
Analyses were conducted using data from a population-based
cross-sectional study carried out in Tumbes, a semiurban area
in the north of Peru. Based on projections of the 2007 national
census, Tumbes has 243,000 inhabitants in an area of 4670 km2
[19]. The rationale for selecting this setting was because preva-
lence of obesity, by body mass index (32% vs. 18%), and T2DM,
by fasting plasma glucose (10% vs. 7%), is over the national
average [20].
2.2.  Participants
Eligible participants were those aged between 30 and 69 years,
full time resident in the study area (i.e. ≥6 months) and able
to understand procedures and provide informed consent.
Women that reported being pregnant or individuals having
any physical disability preventing anthropometric measure-
ments (weight, height, blood pressure or waist circumference)
or those bedridden were excluded from the study.
A sex-stratified, single-stage random sampling strategy
was conducted using the most updated census available in
the study area (2014). To avoid potential clustering of behav-
ioral factors, only one participant per household was invited
to participate in the study.
2.3.  Outcome
T2DM was the outcome variable of interest, and was
defined according to the World Health Organization thresh-
old using the OGTT [7]. Individuals who were not aware
of having T2DM diagnosis and had fasting glucose level
≥126 mg/dL (≥7.0 mmol/L) or 2-h plasma glucose ≥200 mg/dL
(≥11.1 mmol/L) were classified as undiagnosed T2DM.
2.4.  Predictors
Socio-demographic, behavioral and anthropometric variables
included in the manuscript were those related to the risk
models evaluated: FINDRISC [13], LA-FINDRISC [18], and the
Peruvian Risk Score [21]. These variables were: age (in years),
body mass index (in kg/m2), waist circumference (in cm), phys-
ical activity (at least 30 min  per day), daily consumption of
fruits and vegetables (at least one portion per day), history
of anti-hypertensive drug treatment (yes vs. no), history of
high blood glucose (whether participant has ever been found
to have high blood glucose in a health examination, during
an illness or during pregnancy: yes vs. no), and family history
of T2DM (score according to relatives with T2DM diagnosis).
Information about scoring of these risk models is available in
Appendix A (Tables A1 and A2).
2.5.  Procedures
After informed consent, participant’s data was collected using
tablets and measurements were obtained by well-trained
staff. Participants responded to a face-to-face questionnaire.
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An application built using Open Data Kit (ODK) was uti-
lized using tablets. Using the application, we  obtained data
about factors potentially associated with T2DM, including
sociodemographic, behavioral variables, personal medical his-
tory, and familial medical history focused mainly on glucose
metabolism disorder. Specific questions of the risk models
were also included.
After completing questionnaires, measurements of stand-
ing height were carried out using a stadiometer and
standardized procedures. Weight was assessed using a bio-
electrical impedance device (TBF-300A, TANITA Corporation,
Tokyo, Japan), as well as waist circumference was assessed in
triplicate using standard techniques. Heart rate, systolic and
diastolic blood pressure were also evaluated in triplicate using
an automatic monitor OMRON HEM-780 (OMRON Healthcare,
Illinois, US), previously validated for adult population.
Trained laboratory staff explained procedures for blood
sample collection. Participants were asked to provide venous
blood sample for oral glucose tolerance test (OGTT) after a
minimum of 8 and a maximum of 12 h of fasting. First blood
sampling was obtained at the first moment of the appoint-
ment, after verifying fasting period was accomplished. A total
of 7.5 ml  of venous blood sample was drawn to assess fasting
glucose. After that, a load of 75 g of anhydrous glucose in a vol-
ume  of 300 ml  was used as recommended [7]. Two hours after,
a new blood sample was obtained to measure glucose levels. In
the mid-time, questionnaires and clinical measurements were
performed. Blood testing was carried out by a certified Peru-
vian laboratory located in Lima. Laboratory staff was blinded
to results of questionnaires and measurements. Glucose was
measured in serum using a Cobas Modular Platform auto-
mated analyzer and reagents supplied by Roche Diagnostics.
Quality control for glucose measurements had <1 for the coef-
ficient of variation, a reference range provided by Bio-Rad, an
independent assessment company (www.biorad.com).
2.6.  Statistical  analyses  methods
Analysis was performed using STATA 13.0 for Windows (Stata-
Corp, College Station, TX, US). Initially, characteristics of study
population were tabulated using proportions in the case of cat-
egorical variables, and mean and standard deviation (SD) for
continuous variables. After overall participants’ description,
all cases of known T2DM were further excluded from analy-
ses. Then, the prevalence and 95% confidence interval (95% CI)
of undiagnosed T2DM was estimated.
Scoring of FINDRISC, LA-FINDRISC and Peruvian Risk Score
was determined using original coefficients. Then, diagnostic
accuracy of these scores was estimated using the c-statistic
and graphically with the area under the ROC curve. Opti-
mal  empirical cut-off following the method suggested by
Youden was estimated [22], and sensitivity and specificity
were reported. Comparison between diagnostic accuracy of
risk scores was conducted using the roccomp command in
STATA.
Finally, the FINDRISC was simplified by including only vari-
ables independently associated with undiagnosed T2DM in
our sample using backward elimination strategy in logistic
regression. The risk factors in the simplified model were each
assigned a weighted score (i.e. by dividing the regression coef-
ficients in the final model by the lower coefficient and then
rounding them up to the nearest integers as in a previous
report) [23]. Diagnostic accuracy of the simplified FINDRISC
was also assessed using area under the ROC curve as well as
sensitivity and specificity.
2.7.  Ethics
The protocol, informed consent and questionnaires were
approved by Ethical Institutional Committees at the Universi-
dad Peruana Cayetano Heredia, Lima, Peru, and London School
of Hygiene and Tropical Medicine, London, UK.  This work
has been carried out in accordance with the Declaration of
Helsinki.
3.  Results
3.1.  Characteristics  of  the  study  population
A total of 2114 individuals were invited to participate in the
study; 486 (22.9%) rejected participation and 16 (0.8%) women
were pregnant and further excluded. Of the 1612 (76.3%) par-
ticipants enrolled in the study, three did not complete all blood
procedures; and therefore, only 1609 were further analyzed.
Overall, the mean age of the analyzed sample was 48.2 (SD:
10.6) and 810 (50.3%) were women. About a third of the popu-
lation had <7 years of education, and two thirds were currently
working. Detailed characteristics of the study population are
shown in Table 1.
3.2.  Prevalence  of  T2DM  and  undiagnosed  T2DM
A total of 176 (11.0%; 95% CI: 9.4%–12.5%) out of 1609 partici-
pants were classified as having T2DM. One hundred five (6.5%;
95% CI: 5.4%–7.8%) individuals were aware of T2DM diagnosis
and were excluded from further analysis. Based on the OGTT
results, 71 (4.7%; 95% CI: 3.7%–5.8%) were classified as having
undiagnosed T2DM. Of the 71 who met  criteria for T2DM on
OGTT, 56 (78.9%) met  diagnostic criteria based on fasting glu-
cose alone. Characteristic of those with OGTT results (n = 1504)
were similar to those of the total study population (n = 1609),
except in the case of self-reported history of high glucose lev-
els (Table 1).
3.3.  Diagnostic  accuracy  of  risk  score  models  for
undiagnosed  T2DM
The mean score of the FINDRISC was 8.9 (SD: 4.2, range: 0–24)
points, whereas results for the LA-FINDRISC and the Peruvian
Risk Score were 8.6 (SD: 4.4, range: 0–24) and 1.5 (SD: 1.1, range:
0–4), respectively.
When assessing the diagnostic accuracy of the FINDRISC,
the area under the ROC curve was 0.69 (95% CI: 0.64–0.74), with
an empirical optimal cut-off of 11, and a sensitivity of 69%;
whereas the area under the ROC curve for the LA-FINDRISC
was 0.68 (95% CI: 0.63–0.74), with a cut-off of 10, and a sen-
sitivity of 70.4%. When assessing the diagnostic accuracy of
the Peruvian Risk Score, the area under the ROC curve was
0.64 (95% CI: 0.58–0.70), with an empirical cut-off of 2, and a
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Table 1 – Characteristics of the study population: comparison between total population and those with OGTT results.
Total population With OGTT results
N = 1609 N = 1504
N (%) N (%)
Sex Female 810 (50.3%) 750 (49.9%)
Age Mean (SD) 48.2 (10.6) 47.6 (10.6)
Education level <7 years 519 (32.3%) 466 (31.0%)
7–11 years 749 (46.6%) 708 (47.1%)
12+ years 341 (21.2%) 330 (21.9%)
Socioeconomic status (tertiles) Lowest 540 (33.6%) 497 (33.1%)
Middle 550 (34.2%) 517 (34.4%)
Highest 519 (32.3%) 490 (32.6%)
Currently working Yes 1091 (67.8%) 1035 (68.8%)
Health insurance Yes 1469 (91.3%) 1368 (91.0%)
T2DM in first degree-relatives Yes 539 (33.5%) 468 (31.1%)
Daily smoking Yes 92 (5.7%) 86 (5.7%)
Alcohol disorder Yes 121 (7.5%) 121 (8.1%)
Physically active (≥30 min/day) Yes 1098 (68.2%) 1036 (68.9%)
Fruits and vegetables intake At least one/day 841 (52.3%) 789 (52.5%)
Body mass index (kg/m2) Mean  (SD) 28.0 (4.6) 28.0 (4.7)
Obesity by BMI BMI ≥30 kg/m2 476 (29.6%) 450 (29.9%)
Waist circumference (cm) Mean (SD) 93.7 (10.4) 93.6 (10.4)
Obesity by WC Based on IDF 1277 (79.4%) 1186 (78.9%)
Systolic blood pressure (mmHg) Mean (SD) 119.9 (16.7) 119.5 (16.3)
Diastolic blood pressure (mmHg) Mean (SD) 79.7 (10.4) 79.5 (10.3)
Blood pressure treatment Yes 128 (8.0%) 106 (7.1%)
Hypertension status Yes 417 (25.9%) 370 (24.6%)
Self-reported high glucose Yes 159 (9.9%) 56 (3.7%)
Table 2 – Diagnostic accuracy of risk score models for undiagnosed T2DM.
FINDRISC LA-FINDRISC Peruvian Risk Score Simplified FINDRISC
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Area under the ROC curve 0.69 (0.64–0.74) 0.68 (0.63–0.74) 0.64 (0.58–0.70) 0.71 (0.66–0.76)
Empirical cut-off 11 10 2 3
Sensitivity 69.0% (56.9%–79.5%) 70.4% (58.4%–80.7%) 64.8% (52.5%–75.8%) 85.9% (75.6%–93.0%)
Specificity 66.8% (64.3%–69.2%) 59.1% (56.5%–61.7%) 53.7% (51.0%–56.3%) 46.7% (44.1%–49.3%)
Positive predictive value 9.4% (7.0%–12.2%) 7.9% (5.9%–10.2%) 6.4% (4.8%–8.6%) 7.4% (5.7%–9.4%)
Negative predictive value 97.8% (96.6%–98.6%) 97.6% (96.3%–98.5%) 96.8% (95.4%–97.9%) 98.5% (97.3%–99.3%)
Likelihood ratio positive 2.1 (1.8–2.5) 1.7 (1.5–2.0) 1.4 (1.2–1.7) 1.6 (1.5–1.8)
Likelihood ratio negative 0.5 (0.3–0.7) 0.5 (0.4–0.7) 0.7 (0.5–0.9) 0.3 (0.2–0.5)
Diagnostic odd ratio 4.5 (2.7–7.5) 3.4 (2.1–5.8) 2.1 (1.3 –3.5) 5.3 (2.8–10.4)
sensitivity of 64.8% (See details in Table 2). There were no dif-
ferences in the diagnostic accuracy of the aforementioned risk
scores (p = 0.15).
3.4.  Adaptation  and  simplification  of  FINDRISC  for
Peruvian  population
When simplifying FINDRISC, variables independently asso-
ciated with undiagnosed T2DM were: waist circumference
(p = 0.008), blood pressure treatment (p = 0.004), history of high
blood glucose (p = 0.005), and family history of T2DM (p = 0.01).
Coefficients and scores are detailed in Table 3. The area under
the ROC curve of the simplified FINDRISC was 0.71 (95% CI:
0.66–0.76), and with an empirical cut-off ≥3, the sensitivity
and specificity were 85.9% and 46.7%, respectively. Thus, the
diagnostic accuracy of the simplified FINDRISC score was sim-
ilar to the FINDRISC (p = 0.24) and LA-FINDRISC (p = 0.19), but
superior than the Peruvian Risk Score (p = 0.02, Fig. 1)
Fig. 1 – Comparison of area under the ROC curves using the
FINDRISC, LA-FINDRISC, the Peruvian Risk Score and the
simplified risk scores.
Please cite this article in press as: A. Bernabe-Ortiz, et al., Diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for undiagnosed
T2DM in Peruvian population, Prim. Care Diab. (2018), https://doi.org/10.1016/j.pcd.2018.07.015
ARTICLE IN PRESSPCD-714; No. of Pages 9
p r i m a r y c a r e d i a b e t e s x x x ( 2 0 1 8 ) xxx–xxx 5
Table 3 – Beta coefficients of the simplified FINDRISC for undiagnosed T2DM in Peruvian population.
Bivariable model Final modela Score
Coef. (SE) OR (95% CI) Coef. (SE) OR (95% CI)
Age (vs. <45 years)
≥45 and <55 years 0.39 (0.29) 1.48 (0.84–2.62)
≥55 and <65 years 0.26 (0.33) 1.29 (0.68–2.44)
≥65 years 0.34 (0.50) 1.40 (0.52–3.74)
Body mass index (vs.<25 kg/m2)
≥25 and <30 kg/m2 0.46 (0.36) 1.58 (0.78–3.21)
≥30 kg/m2 0.99 (0.36) 2.70 (1.34–5.43)
Waist circumference (vs. F < 80 cm/M < 94 cm)
F: ≥80 and <88 cm/M: ≥94 and <102 cm 1.10 (0.44) 3.02 (1.26–7.21) 1.04 (0.45) 2.82 (1.17–6.76) 2 (vs. 0)
F: ≥88 cm/M: ≥102 cm 1.46 (0.41) 4.31 (1.92–9.65) 1.30 (0.42) 3.65 (1.62–8.26) 3 (vs. 0)
Physical activity (vs. no)
At least 30 min per day 0.13 (0.26) 1.14 (0.69–1.89)
Fruits and vegetables intake (vs. no)
At least once per day −0.04 (0.24) 0.96 (0.59–1.54)
Blood pressure medication (vs. no)
Yes 1.17 (0.33) 3.22 (1.71–6.10) 0.98 (0.33) 2.65 (1.38–5.12) 2 (vs. 0)
History of high blood glucose levels (vs. no)
Yes 1.32 (0.40) 3.74 (1.70–8.25) 1.19 (0.42) 3.28 (1.44–7.47) 2 (vs. 0)
Family history of T2DM (vs. no)
Parent, brother, sister or own child 0.63 (0.25) 1.87 (1.16–3.03) 0.61 (0.25) 1.84 (1.13–3.00) 1 (vs. 0)
a The final model was created by backward elimination, keeping only variables significantly associated with undiagnosed T2DM.
4.  Discussion
4.1.  Main  findings
Our findings demonstrated that the diagnostic accuracy of
the FINDRISC, LA-FINDRISC and Peruvian Risk Score for undi-
agnosed T2DM was similar. However, a simplified version of
the FINDRISC, with only four variables, can perform similar
to the FINDRISC and LA-FINDRISC, but better than the Peru-
vian Risk Score. These four variables (i.e. waist circumference,
self-report of blood pressure treatment, history of high blood
glucose, and family history of type 2 diabetes mellitus) are easy
to obtain in clinical practice and thus, could be implemented
for detecting undiagnosed T2DM at the population level. In
addition, the prevalence of T2DM in the study population was
relatively high (11% compared to the national Peruvian aver-
age of 7%).
4.2.  Comparison  with  previous  studies
Worldwide, there are many  risk scores created for detecting
cases of undiagnosed T2DM, though many  of them are for
Caucasian [23–25] and Asian populations [26–28]. The FIND-
RISC is a well-known risk score created initially for incident
T2DM cases, but currently can be used for T2DM screening [13].
However, previous experience has established that a risk score
needs to be adapted, validated, or calibrated in the population
where this is planned to be applied as prevalence and distri-
bution of outcomes and risk factors are not similar between
settings [29].
The FINDRISC had a moderate performance for T2DM
screening in Peruvian population. Our results were similar to
previous studies in Latin America [17,30] and other Spanish-
speaking populations like the study of Salinero-Fort et al.
in Madrid [31], although the diagnostic accuracy was lower
than in Asian [15] or European [13,32] populations. Moreover,
according to our logistic regression modeling, the original
FINDRISC can be simplified to only four variables to slightly
improve the diagnostic accuracy. A previous report has high-
lighted the need of a Latin-American version of the FINDRISC
(LA-FINDRISC) with changes in the cut-offs of waist circum-
ference [18]; however, our analyses confirm no difference
between the FINDRISC and LA-FINDRISC in Peruvian popula-
tion, and hence, the original score should be kept.
4.3.  Prevalence  of  undiagnosed  T2DM
This can be the first study estimating the prevalence of T2DM
and undiagnosed T2DM using OGTT in Peru. To our knowledge,
there are only two previous studies using nationally represen-
tative samples to estimate T2DM prevalence, but using fasting
glucose: one conducted in 2004–2005 reporting a prevalence
of 5% [33], and the other one carried out in 2010–2012 with
an estimate of 7% [34]. This number, however, increased up to
10% in Tumbes, in the north of Peru [20], setting where this
study was conducted. Using OGTT, our results show that the
prevalence of T2DM in Tumbes is 11%, value much greater than
the national estimate of 7% [34]. Thus, our results are alarm-
ing as we are witnessing the increasing burden of T2DM in
resource-constrained settings in a very short period.
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Table 4 – Diagnostic accuracy and implications of using a risk score.
Risk score Sensitivity Specificity At high risk of T2DM T2DM cases detected Subjects without T2DM
FINDRISC 69.0% 66.8% 371 (37.1%) 76 595
LA-FINDRISC 70.4% 59.1% 441 (44.1%) 77 526
Peruvian Risk Score 64.8% 53.7% 483 (48.3%) 71 478
Simplified FINDRISC 85.9% 46.7% 568 (56.8%) 94 416
All the estimates were calculated assuming that 1000 individuals were screened and a prevalence of 11% of T2DM.
Regarding undiagnosed T2DM, our estimates show that
about 60% of individuals with T2DM are aware of their disease.
Using data of the PERU MIGRANT Study [35], overall T2DM
diagnosis awareness was 71%, yet estimates ranged from 0%
in rural settings to 74% in urban areas [36]. On the other hand,
results using the baseline of the CRONICAS Cohort Study [20]
showed that, among all T2DM cases, 61.3% were aware of their
diagnosis. In addition, our results are compatible with current
reports (range: 24% to 62%) [4]. However, although there are
effective interventions to control T2DM [37,38], unawareness
imposes a large economic burden on individuals and fami-
lies as well as health systems, mainly in resource-constrained
settings.
4.4.  Public  Health  Relevance
The implementation of the FINDRISC in our population could
be useful to detect T2DM cases. According to calculations
based on a hypothetic sample of 1000 participants (Table 4),
the FINDRISC would detect 76 cases in 371 classified at high
risk of T2DM, and for instance, only 37.1% of the 1000 indi-
viduals would require a confirmatory test. On the other hand,
using the simplified FINDIRSC, with higher sensitivity, a total
of 94 cases would be detected, but 568 would be classified as at
high risk of T2DM, and for instance, 53% more  people would
need a confirmatory test, with the consequent increment of
the resources and costs.
The advantage of the FINDRISC lies on its self-report
nature (6 items are easy questions) and the presence of two
anthropometrical measurements (body mass index and waist
circumference). Our simplified version of the FINDRISC con-
tains only three self-reported items and waist circumference,
an anthropometric marker that is easy to measure, making
this score implementable in clinical practice. The simplified
version of the FINDRISC included waist circumference instead
of body mass index as the first one provides a better indicator
of accumulation of visceral fat and glucose metabolism dereg-
ulation [39]. As one of the barriers to the uptake of risk scores
by health practitioners includes the lack of practicality of using
the scores and their components [40], an easy measure as the
waist circumference might minimize this compared to the use
of stadiometer and scale for height and weight of the BMI.
In 2016, the Peruvian Ministry of Health published the
Guide of Clinical Practice for Diagnosis, Treatment and Control
of Type 2 Diabetes Mellitus in Primary Care. In that guideline,
there is no recommendation about the use of risk scores for
T2DM screening, but, recommends using fasting plasma glu-
cose among adults between 40 and 70 years with overweight or
obesity [41]. The FINDRISC appears then as a very good alter-
native to screen individuals, especially in areas (semiurban
and rural settings) where fasting glucose or other blood mark-
ers are not available. A recent systematic review has pointed
out the benefit of a two-step approach for T2DM screening, but
no study was found in Latin American region [9]. Therefore,
there is need to estimate the cost related of using a two-step
approach for detecting cases of undiagnosed T2DM in our con-
text.
4.5.  Strengths  and  limitations
This study benefits from the use of OGTT to diagnose T2DM.
Although data comes from a small region in Peru, the sam-
ple was representative from the study area and, for instance,
results are inferable. However, this study has also some limita-
tions. First, selection bias might arise as the population sample
only included participants aged from 30 to 69 years from a
small region in Peru, and thus, our findings can be limited to
that group. Thus, further scrutiny is needed to appropriately
validate proposed tools at the national level. Second, some
desirability and recall bias might be present as some ques-
tions show results much higher than expected. For example,
more than two thirds participants reported being physically
active (i.e. exercise for ≥30 min  per day) and almost half of
them reported consuming fruits and vegetables at least once
a day. Third, power of the study might be an issue as some
variables associated with T2DM were not significant in our
model. However, the four variables independently associated
with undiagnosed T2DM have been associated also in other
risk scores in Latin America [21,30,42]. In addition, the sim-
plified version of the FINDRISC has been developed with the
data of this study and for instance further external validation
and evaluation is required. Finally, as in the original FINDRISC,
our model was created on the idea of risk stratification instead
of individualization [43]; therefore, variables were categorized
instead of being kept as numerical in the risk score. However,
our idea was to conserve a simple score for detecting cases of
undiagnosed T2DM.
5.  Conclusions
The diagnostic accuracy of the FINDRISC, LA-FINDRISC and
Peruvian Risk Score for undiagnosed T2DM was similar. A sim-
plified FINDRISC, with only four variables, can perform similar
or better than aforementioned scores. The FINDRISC or its
simplified version may be useful to detect cases of undiag-
nosed T2DM in resource-constrained settings.
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Appendix  A.
Table A1 – Scoring of FINDRISC and LA-FINDRISC for
undiagnosed T2DM.
FINDRISC LA-FINDRISC
Age:
< 45 years 0 points 0 points
45–54 years 2 points 2 points
55–64 years 3 points 3 points
65+ years 4 points 4 points
Body mass index:
<25 kg/m2 0 points 0 points
Between 25 and < 30 kg/m2 1 point 1 point
≥30 kg/m2 3 points 3 points
Waist circumference:
Men: <94 cm; women: <80 cm 0 points 0 points
Men: 94–102 cm; women:
80–88 cm
3  points 4 points
Men: >102 cm; women: >88 cm 4 points
Physical activity (at least 30 min/day):
Yes 0 points 0 points
No 2 points 2 points
Fruits and vegetables intake:
Every day 0 points 0 points
Not every day 1 point 1 point
Regular medication for hypertension:
No 0 points 0 points
Yes 2 points 2 points
History of high glucose levels:
No 0 points 0 points
Yes 5 points 5 points
Diabetes in relatives:
No 0 points 0 points
Yes, grandparents, cousins,
uncle, aunt
3  points 3 points
Yes, parents, siblings, son,
daughter
5  points 5 points
The difference between FINDRISC and LA-FINDRISC is based on
score on waist circumference.
Table A2 – Scoring of the Peruvian Risk Score for
undiagnosed T2DM.
Peruvian Risk Score
Age:
<55 years 0 points
55+ years 1 point
Waist circumference:
<90 cm 0 points
90 to <100 cm 1 point
100+ cm 2 points
Diabetes in first-degree relatives
No 0 points
Yes 1 point
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